BioSpace News Archive

Acarix, a leader in advanced acoustic-based cardiac diagnostics, announces the appointment of three new advisors to its team.

Blueprint Medicines Corporation reported financial results and provided a business update for the fourth quarter and full year ended December 31, 2023 and provided financial guidance.

The Defense Threat Reduction Agency’s Joint Science and Technology Office for the Chemical and Biological Defense Program has awarded, through the Medical CBRN [Chemical, Biological, Radiological, and Nuclear] Defense Consortium requirement 22-05, “Adjuvant Activity to Vaccines Prototype,” a 5-year contract totaling up to $31 million including program options to the team of Ginkgo Bioworks, Inc.

Alkermes plc reported financial results for the quarter and year ended Dec. 31, 2023 and provided financial expectations for 2024.

Intellia Therapeutics, Inc. and ReCode Therapeutics announced a strategic collaboration to develop novel genomic medicines for the treatment of cystic fibrosis.

Selkirk Pharma, Inc. announced the Aseptic Process Simulation qualification of its sterile manufacturing facility and newly available fill/finish capacity.

The New England Journal of Medicine published results from a positive Phase 2 clinical trial demonstrating frexalimab significantly slowed disease activity in people with relapsing multiple sclerosis, corresponding to 89% and 79% reduction in new gadolinium-enhancing T1 brain lesions at Week 12 in the high- and low-dose treatment arms compared to placebo, meeting the study’s primary endpoint.

Vaccinex, Inc. announced that it will effect a 1-for-14 reverse stock split of its issued common stock, effective at 5:00 p.m. Eastern Time on Monday, February 19, 2024.

Panbela Therapeutics, Inc., a clinical stage company developing disruptive therapeutics for the treatment of patients with urgent unmet medical needs, announced that, has regained compliance with applicable listing standards of The Nasdaq Stock Market for bid price and publicly held shares.

Osivax announced that the first participant has been vaccinated in its new Phase 1 trial evaluating OVX033, a broad-spectrum sarbecovirus vaccine candidate.